Table of content
Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Molecule Type
1.1.3. Application
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective-1
1.4.2. Objective-2
1.4.3. Objective-3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. The rising frequency of patent expirations for blockbuster drugs is expected to strengthen the market for generic injectables
3.2.1.2. Streamlined regulatory pathway and low cost of generics
3.2.1.3. Increasing penetration of CDMOs in the generic injectables space
3.2.2. Market Restraint Analysis
3.2.2.1. Presence of substitute therapies
3.2.2.2. Compliance issues while outsourcing
3.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Analysis Tools
3.3.1. Market Analysis - Porter’s Five Forces
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Molecule Type Estimates & Trend Analysis
4.1. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Molecule Type: Segment Dashboard
4.2. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Molecule Type: Movement Analysis
4.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Molecule Type, 2018 - 2030
4.3.1. Small Molecules
4.3.1.1. Small Molecule U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
4.3.2. Large Molecules
4.3.2.1. Large Molecule U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, 2018 to 2030 (USD Million)
Chapter 5. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Application Estimates & Trend Analysis
5.1. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Application: Segment Dashboard
5.2. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market, By Application: Movement Analysis
5.3. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
5.3.1. Oncology
5.3.1.1. Oncology U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
5.3.2. Immunology
5.3.2.1. Immunology U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
5.3.3. Antidiabetic
5.3.3.1. Antidiabetic U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
5.3.4. Neurology
5.3.4.1. Neurology U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
5.3.5. Cardiovascular
5.3.5.1. Cardiovascular U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
5.3.6. Respiratory
5.3.6.1. Respiratory U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
5.3.7. Others
5.3.7.1. Others U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market 2018 to 2030 (USD Million)
Chapter 6. U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market: Country Estimates & Trend Analysis
6.1. U.S.
6.1.1. Key Country Dynamics
6.1.2. Competitive Scenario
6.1.3. Regulatory Framework
6.1.4. U.S. Market Estimates and Forecasts, 2018 - 2030
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.1.1. Innovators
7.1.2. Market Leaders
7.1.3. Emerging Players
7.1.4. Company Market Share Analysis, 2022
7.2. Company Profiles
7.2.1. Hikma Pharmaceuticals plc
7.2.1.1. Company Overview
7.2.1.2. Financial Performance
7.2.1.3. Service Benchmarking
7.2.1.4. Strategic Initiatives
7.2.2. Pfizer Inc.
7.2.2.1. Company Overview
7.2.2.2. Financial Performance
7.2.2.3. Service Benchmarking
7.2.2.4. Strategic Initiatives
7.2.3. Fresenius Kabi
7.2.3.1. Company Overview
7.2.3.2. Financial Performance
7.2.3.3. Service Benchmarking
7.2.3.4. Strategic Initiatives
7.2.4. Sandoz AG
7.2.4.1. Company Overview
7.2.4.2. Financial Performance
7.2.4.3. Service Benchmarking
7.2.4.4. Strategic Initiatives
7.2.5. Jubilant Pharma Limited
7.2.5.1. Company Overview
7.2.5.2. Financial Performance
7.2.5.3. Service Benchmarking
7.2.5.4. Strategic Initiatives
7.2.6. Baxter
7.2.6.1. Company Overview
7.2.6.2. Financial Performance
7.2.6.3. Service Benchmarking
7.2.6.4. Strategic Initiatives
7.2.7. PCI Pharma Services
7.2.7.1. Company Overview
7.2.7.2. Financial Performance
7.2.7.3. Service Benchmarking
7.2.7.4. Strategic Initiatives
7.2.8. Gland Pharma Limited (USA)
7.2.8.1. Company Overview
7.2.8.2. Financial Performance
7.2.8.3. Service Benchmarking
7.2.8.4. Strategic Initiatives
7.2.9. Dr. Reddy’s Laboratories Ltd.
7.2.9.1. Company Overview
7.2.9.2. Financial Performance
7.2.9.3. Service Benchmarking
7.2.9.4. Strategic Initiatives
7.2.10. Grand River Aseptic Manufacturing
7.2.10.1. Company Overview
7.2.10.2. Financial Performance
7.2.10.3. Service Benchmarking
7.2.10.4. Strategic Initiatives
Chapter 8. Kol Commentary/Recommendations
List of Tables
Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 U.S. Generic Injectables Pharmaceutical Contract Manufacturing market, by Molecule Type, 2018 - 2030 (USD Million)
Table 4 U.S. Generic Injectables Pharmaceutical Contract Manufacturing market, by Application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modelling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary interviews in U.S.
Fig. 8 Market Snapshot
Fig. 9 Segment Snapshot
Fig. 10 Segment Snapshot
Fig. 11 Competitive Landscape Snapshot
Fig. 12 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Segmentation
Fig. 13 Parent market outlook (2022)
Fig. 14 Related/ancillary market outlook (2022)
Fig. 15 Market driver relevance analysis (Current & future impact)
Fig. 16 Market restraint relevance analysis (Current & future impact)
Fig. 17 Porter’s Five Forces analysis
Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 19 U.S. Generic Injectables Pharmaceutical Contract Manufacturing Market Molecule Type outlook: Segment dashboard
Fig. 20 U.S. Generic Injectables Pharmaceutical Contract Manufacturing: Molecule Type movement analysis
Fig. 21 Small Molecule market, 2018 - 2030 (USD Million)
Fig. 22 Large Molecule market, 2018 - 2030 (USD Million)
Fig. 23 U.S. Generic Injectables Pharmaceutical Contract Manufacturing market Application outlook: Segment dashboard
Fig. 24 U.S. Generic Injectables Pharmaceutical Contract Manufacturing market: Application movement analysis
Fig. 25 Oncology market, 2018 - 2030 (USD Million)
Fig. 26 Immunology market, 2018 - 2030 (USD Million)
Fig. 27 Antidiabetic market, 2018 - 2030 (USD Million)
Fig. 28 Neurology market, 2018 - 2030 (USD Million)
Fig. 29 Cardiovascular market, 2018 - 2030 (USD Million)
Fig. 30 Respiratory market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 U.S. market, 2018 - 2030 (USD Million)